NUCLEOLIN and cancer: Another important conclusion of the work presented here, and of the resulting model (Fig. 9), is that it highlights two potential therapeutic strategies that may be exploited to reveal EBV-related cancers to the immune system: by targeting either rG4 of EBNA1 mRNA (for example by means of G4-ligands), or type I PRMTs, and therefore both the interaction between EBNA1 and NCL proteins (this study) and also the interaction between NCL and rG4 of EBNA1 mRNA [38].